Compare Franklin FTSE South Korea ETF (FLKR) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin FTSE South Korea ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? Franklin FTSE South Korea ETF trades at $49.76 (market cap $1.67B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 5.1× Franklin FTSE South Korea ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Franklin FTSE South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FLKR | HNGE | |
|---|---|---|
Market Cap | $1.67B | $8.47B |
Volume | 880,778 | 1,624,526 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $105.14 |
52-Week Low | $28.48 | $31.17 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLKR (Franklin FTSE South Korea ETF) is trading at $54.89, down 2.03% with a bearish technical signal (16 sell vs 6 buy signals). The ETF faces pressure from semiconductor sector volatility and rising global yields, though some analysts see current levels as a potential buying opportunity. Technical indicators show strong resistance at $55-$56 with support at $53-$54 levels. The fund remains heavily concentrated in Korean memory chip giants Samsung and SK Hynix, making it highly sensitive to AI and semiconductor cycles.
While FLKR faces near-term headwinds from semiconductor volatility and macroeconomic pressures, long-term prospects remain tied to AI-driven demand for Korean tech. The current discount to growth expectations presents opportunity, but investors must weigh concentration risk against potential semiconductor recovery. Key risks include political tensions, currency fluctuations, and global interest rate environment.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Franklin FTSE South Korea ETF
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
